Atropine

The exact Darnitsa 1 mg/ml ampoule has a current sourced Georgian human authorisation and an official exact manufacturer instruction, but the exact brand is not authorised in the checked EU/EEA, GB or US registers. A separate EU-authorised 1 mg/ml veterinary injection supports formulation/route applicability, while this human product remains off-label.

Atropine is an established antimuscarinic with a current EU-authorised canine injectable comparator. RECOVER recommends it for haemodynamically compromising bradycardia and allows one early dose in selected nonshockable CPR, but CPR outcome evidence is low and high-vagal benefit is expert opinion. A 102-dog poisoning cohort and toxicology guidance support control of muscarinic signs; atropine neither reverses nicotinic weakness nor replaces ventilation, decontamination or an oxime when indicated.

Atropine has a narrow indication-dependent margin rather than a generally benign profile: excessive or repeated dosing can cause tachycardia/tachyarrhythmia, reduced cardiac output, hyperthermia, ileus, urinary retention, thickened airway secretions, mydriasis/glaucoma aggravation and central excitation. ECG, perfusion and clinical endpoints make short monitored emergency use manageable; obstruction, glaucoma and pre-existing tachyarrhythmia require particular caution.

The 1 mg/ml single-use 1 ml ampoule is familiar, needs no reconstitution and supports accurate IV/IM/SC withdrawal for many dogs. Small bradycardia doses still need a finely graduated syringe, while severe poisoning can require repeated multi-ampoule dosing and substantial stock because the titrated dose may be tens of times higher; opened remainder is discarded.

The exact Darnitsa 1 mg/ml ampoule has a current sourced Georgian human authorisation and an official exact manufacturer instruction, but the exact brand is not authorised in the checked EU/EEA, GB or US registers. A separate EU-authorised 1 mg/ml veterinary injection supports formulation/route applicability, while this human product remains off-label.

Atropine has a current EU-authorised feline injectable comparator and RECOVER support for haemodynamically compromising bradycardia and one selected early CPR dose, although outcome evidence is low. A 39-cat poisoning cohort and a successful severe-toxicosis CRI case support muscarinic control but do not establish comparative efficacy. It does not reverse nicotinic weakness or replace ventilation, decontamination or an oxime.

Atropine has a narrow indication-dependent margin rather than a generally benign profile: excessive or repeated dosing can cause tachycardia/tachyarrhythmia, reduced cardiac output, hyperthermia, ileus, urinary retention, thickened airway secretions, mydriasis/glaucoma aggravation and central excitation. ECG, perfusion and clinical endpoints make short monitored emergency use manageable; obstruction, glaucoma and pre-existing tachyarrhythmia require particular caution.

The 1 mg/ml single-use 1 ml ampoule is ready to use and usually supplies enough drug for feline bradycardia or initial poisoning management. A small cat at the low bradycardia range may require only a few hundredths of a millilitre, demanding a finely graduated syringe or validated dilution; repeated toxicosis dosing still needs close endpoint monitoring and opened remainder is discarded.

The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.

Current veterinary consensus supports atropine 1% for miosis, painful reflex ciliary spasm and blood-aqueous-barrier stabilisation in corneal disease/anterior uveitis. Direct canine pharmacodynamics support biological activity, but exact-product diseased-eye comparative outcomes and one universal regimen are absent.

One-drop canine studies document an early IOP rise, and repeated daily exposure can suppress tear production beyond treatment. Systemic antimuscarinic absorption, glaucoma, corneal-surface compromise and prolonged effects require selection, minimum exposure and monitoring; exact-product veterinary safety is unstudied.

A 5 ml dropper and 14-day in-use period can support a short ophthalmic course, but frequency is case-specific and continuing care requires restraint, IOP/tear reassessment, punctal occlusion and contamination control.

The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.

Atropine reliably dilates and cyclopleges, but current veterinary consensus explicitly advises against it for routine lens/fundus dilation because a shorter-acting agent is better matched to that task; prolonged effect is not added diagnostic benefit.

One-drop canine studies document an early IOP rise, and repeated daily exposure can suppress tear production beyond treatment. Systemic antimuscarinic absorption, glaucoma, corneal-surface compromise and prolonged effects require selection, minimum exposure and monitoring; exact-product veterinary safety is unstudied.

Instillation is simple, but 24-hour-to-7-day-or-longer dilation is disproportionate for a routine lens/fundus examination and complicates recovery, owner counselling and repeat assessment compared with short-acting tropicamide.

The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.

Veterinary consensus supports therapeutic cycloplegia, pain relief and synechiae prevention in feline anterior uveitis/corneal disease, but exact-product diseased-eye outcomes are absent and newer direct data show that 1% is less tolerable than 0.1% in healthy cats.

Direct 1% feline studies show reproducible IOP elevation, marked immediate discomfort and prolonged pupil non-responsiveness. Bitter nasolacrimal drainage can trigger salivation/vomiting, systemic absorption remains possible, and exact-product diseased-cat safety is unstudied.

A dropper bottle is simple, but feline bitter-taste distress, restraint, baseline/follow-up tonometry, minimum exposure, prolonged effects and 14-day discard create meaningful clinical burden.

The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.

One-drop feline studies confirm marked dilation, but current veterinary consensus advises against routine lens/fundus use and direct feline data show prolonged pupil non-responsiveness; reliable dilation does not make 1% atropine a good routine diagnostic default.

Direct 1% feline studies show reproducible IOP elevation, marked immediate discomfort and prolonged pupil non-responsiveness. Bitter nasolacrimal drainage can trigger salivation/vomiting, systemic absorption remains possible, and exact-product diseased-cat safety is unstudied.

Instillation is simple, but marked immediate discomfort, IOP monitoring and a median 47.5 hours of pupil non-responsiveness in a direct 1% study make this particularly impractical for routine feline lens/fundus examination.

The exact Bioindustria 1 mg/ml ampoule has current sourced Georgian and EU/Italian human authorisations and exact approved product information. A separate 1 mg/ml atropine-sulfate veterinary injection is validly authorised in the EU for dogs and cats by IV, IM and SC routes, strongly supporting formulation/route applicability; this human product itself remains off-label.

Atropine is an established antimuscarinic with a current EU-authorised canine injectable comparator. RECOVER recommends it for haemodynamically compromising bradycardia and allows one early dose in selected nonshockable CPR, but CPR outcome evidence is low and high-vagal benefit is expert opinion. A 102-dog poisoning cohort and toxicology guidance support control of muscarinic signs; atropine neither reverses nicotinic weakness nor replaces ventilation, decontamination or an oxime when indicated.

Atropine has a narrow indication-dependent margin rather than a generally benign profile: excessive or repeated dosing can cause tachycardia/tachyarrhythmia, reduced cardiac output, hyperthermia, ileus, urinary retention, thickened airway secretions, mydriasis/glaucoma aggravation and central excitation. ECG, perfusion and clinical endpoints make short monitored emergency use manageable; obstruction, glaucoma and pre-existing tachyarrhythmia require particular caution.

The 1 mg/ml single-use 1 ml ampoule is familiar, needs no reconstitution and supports accurate IV/IM/SC withdrawal for many dogs. Small bradycardia doses still need a finely graduated syringe, while severe poisoning can require repeated multi-ampoule dosing and substantial stock because the titrated dose may be tens of times higher; opened remainder is discarded.

The exact Bioindustria 1 mg/ml ampoule has current sourced Georgian and EU/Italian human authorisations and exact approved product information. A separate 1 mg/ml atropine-sulfate veterinary injection is validly authorised in the EU for dogs and cats by IV, IM and SC routes, strongly supporting formulation/route applicability; this human product itself remains off-label.

Atropine has a current EU-authorised feline injectable comparator and RECOVER support for haemodynamically compromising bradycardia and one selected early CPR dose, although outcome evidence is low. A 39-cat poisoning cohort and a successful severe-toxicosis CRI case support muscarinic control but do not establish comparative efficacy. It does not reverse nicotinic weakness or replace ventilation, decontamination or an oxime.

Atropine has a narrow indication-dependent margin rather than a generally benign profile: excessive or repeated dosing can cause tachycardia/tachyarrhythmia, reduced cardiac output, hyperthermia, ileus, urinary retention, thickened airway secretions, mydriasis/glaucoma aggravation and central excitation. ECG, perfusion and clinical endpoints make short monitored emergency use manageable; obstruction, glaucoma and pre-existing tachyarrhythmia require particular caution.

The 1 mg/ml single-use 1 ml ampoule is ready to use and usually supplies enough drug for feline bradycardia or initial poisoning management. A small cat at the low bradycardia range may require only a few hundredths of a millilitre, demanding a finely graduated syringe or validated dilution; repeated toxicosis dosing still needs close endpoint monitoring and opened remainder is discarded.